3 Key Takeaways
Plain English Summary- 01Core Finding
We argue that this misalignment between evidence and regulation is itself a potential source of patient harm, through persistent underdosing and inconsistent interpretive guidance.
- 02Study Evidence
Tested in a randomized controlled trial at the randomized clinical trial stage.
- 03Practical Meaning
Controlled trial findings show causal benefit under protocol rules; real-world effectiveness can vary across patients.
What This Means for You
Any-grade creatine phosphokinase elevation rises modestly with dose in the largest registry but is inconsistent elsewhere, with a clearer signal of marked elevation at the highest doses. We propose a pragmatic framework (≥8 mg/kg per day for E faecium, 10-12 mg/kg per day in vancomycin-resistant disease, MIC-informed dose selection, β-lactam combination in endocarditis, and weekly creatine phosphokinase monitoring) and call for therapeutic drug monitoring, harmonised breakpoints, prospective studies, and molecular resistance detection.
The Discovery
Despite the absence of US Food and Drug Administration or European Medicines Agency approval, randomised trials, and harmonised susceptibility guidance, daptomycin has become indispensable for the treatment of serious enterococcal bloodstream infections and endocarditis. The Clinical and Laboratory Standards Institute assigns Enterococcus faecium a susceptible dose-dependent category (≤4 mg/L, 8-12 mg/kg per day) and Enterococcus faecalis a susceptible breakpoint (≤2 mg/L, 6 mg/kg per day), whereas the European Committee on Antimicrobial Susceptibility Testing sets no clinical breakpoint, citing insufficient evidence. We argue that this misalignment between evidence and regulation is itself a potential source of patient harm, through persistent underdosing and inconsistent interpretive guidance. Observational data link 10-12 mg/kg per day with lower mortality in patients infected with vancomycin-resistant E faecium. Even so, appropriate dosing frequently does not attain the pharmacodynamic target, because target attainment depends less on the administered dose than on the isolate's minimum inhibitory concentration (MIC), which current methods cannot reliably determine.
How It Works, Simply
This infectious disease research focuses on pathogen neutralization & host immune priming. Researchers evaluated it using a randomized controlled trial at the randomized clinical trial stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
We argue that this misalignment between evidence and regulation is itself a potential source of patient harm, through persistent underdosing and inconsistent interpretive guidance.
- 02Study Evidence
Tested in a randomized controlled trial at the randomized clinical trial stage.
- 03Practical Meaning
Controlled trial findings show causal benefit under protocol rules; real-world effectiveness can vary across patients.
Biological Mechanism & Study Design
Study Design & Cohort
Randomized controlled trial
Randomized controlled trial · Randomized Clinical Trial
Biological Pathway & Modality
Pathogen neutralization & host immune priming
Intervention: Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling
Experimental Findings & Endpoints
Despite the absence of US Food and Drug Administration or European Medicines Agency approval, randomised trials, and harmonised susceptibility guidance, daptomycin has become indispensable for the treatment of serious enterococcal bloodstream infections and endocarditis.
The Clinical and Laboratory Standards Institute assigns Enterococcus faecium a susceptible dose-dependent category (≤4 mg/L, 8-12 mg/kg per day) and Enterococcus faecalis a susceptible breakpoint (≤2 mg/L, 6 mg/kg per day), whereas the European Committee on Antimicrobial Susceptibility Testing sets no clinical breakpoint, citing insufficient evidence. We argue that this misalignment between evidence and regulation is itself a potential source of patient harm, through persistent underdosing and inconsistent interpretive guidance.
Observational data link 10-12 mg/kg per day with lower mortality in patients infected with vancomycin-resistant E faecium. Even so, appropriate dosing frequently does not attain the pharmacodynamic target, because target attainment depends less on the administered dose than on the isolate's minimum inhibitory concentration (MIC), which current methods cannot reliably determine.
Clinical Translation & Practice Context
Any-grade creatine phosphokinase elevation rises modestly with dose in the largest registry but is inconsistent elsewhere, with a clearer signal of marked elevation at the highest doses.
We propose a pragmatic framework (≥8 mg/kg per day for E faecium, 10-12 mg/kg per day in vancomycin-resistant disease, MIC-informed dose selection, β-lactam combination in endocarditis, and weekly creatine phosphokinase monitoring) and call for therapeutic drug monitoring, harmonised breakpoints, prospective studies, and molecular resistance detection.
The Bottom Line · Clinical Pearl
“We propose a pragmatic framework (≥8 mg/kg per day for E faecium, 10-12 mg/kg per day in vancomycin-resistant disease, MIC-informed dose selection, β-lactam combination in endocarditis, and weekly creatine phosphokinase monitoring) and call for therapeutic drug monitoring, harmonised breakpoints, prospective studies, and molecular resistance detection.”
Published in The Lancet Infectious Diseases · Current Stage: Randomized Clinical Trial